Advanced Biomed Inc. has successfully regained compliance with the Nasdaq Listing Rule 5550(a)(2) after implementing a reverse stock split. The company received a notice from Nasdaq on July 18, 2025, indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share. Following this notification, Advanced Biomed was granted a compliance period of 180 days to rectify the situation. Despite not meeting the requirement by the initial deadline of January 14, 2026, the company appealed the delisting decision on January 21, 2026. A hearing was conducted on February 17, 2026, where the company presented a plan to regain compliance, which included the reverse stock split approved by shareholders on January 12, 2026. On March 12, 2026, the Nasdaq Panel confirmed that the company had maintained a closing bid price of $1.00 or more per share post-split, allowing its common stock to remain listed on the Nasdaq Stock Market. This decision is subject to a one-year monitoring period by the Panel, ensuring that the company adheres to the listing requirements moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.